Found 1 matching record:
HXB2 Location | Gag(77-85) | Gag Epitope Map
View variants at this location |
||||
---|---|---|---|---|---|---|
Epitope |
SLYNTVATL
|
Epitope Alignment | ||||
Variants |
|
|||||
Epitope Name | SL9 | |||||
Species (MHC/HLA) | human(A2) |
Showing 1 of 11 variants.
Variant ID. | 3238 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLcNTVATL |
Mutations | Y/C |
Epitope Location | Y3C |
HXB2 Location | Y79C |
Mutation Type | DHB: diminished HLA binding or increased off-rate |
Method | Chromium-release assay, HLA binding |
Note | Variant peptide SLcNTVATL bound HLA-A*02 at a relative binding of 86% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations. |
Sewell1997 A. K. Sewell, G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. Antagonism of Cytotoxic T Lymphocyte-Mediated Lysis by Natural HIV-1 Altered Peptide Ligands Requires Simultaneous Presentation of Agonist and Antagonist Peptides. Eur. J. Immunol., 27:2323-2329, 1997. PubMed ID: 9341776. Show all entries for this paper.
This is a legacy search page. It is deprecated, will receive no more updates, and will eventually be removed. Please use the new search pages.